AIM
EVOK

Acrospire Investment Management’s Evoke Pharma EVOK Stock Holding History

Acrospire Investment Management’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-17
Closed -$6K – 485
2017
Q2 		$6K Sell
17
-6
-26% -$2.3K 0.01% 1924
2017
Q1 		$10K Sell
23
-49
-68% -$20.1K 0.01% 1863
2016
Q4 		$21K Buy
+72
New +$18.7K 0.01% 1742

Other funds holding EVOK

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acrospire Investment Management's EVOK Position: Q3 2017 in Review

Acrospire Investment Management sold out of Evoke Pharma (EVOK) in Q3 2017, closing a stake of 17 shares — an estimated $6K sold.

Acrospire Investment Management first reported a position in EVOK in Q4 2016 and held it in 3 quarters. The position peaked at $21K in Q4 2016. 21 funds tracked by Wall St. Rank hold EVOK as of Q3 2017.

  • Acrospire Investment Management reported no remaining Evoke Pharma position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 17 Evoke Pharma shares in Q3 2017, an estimated $6K.
  • Acrospire Investment Management first reported a position in Evoke Pharma in Q4 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Evoke Pharma position peaked at $21K in Q4 2016.
  • 21 funds tracked by Wall St. Rank held Evoke Pharma as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.